Key facts
- This page summarizes Onaiza Cadoret-Manier's Form 4/A - Amendment filing for IONIS PHARMACEUTICALS INC (IONS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 04 Sep 2024, 20:42.
Onaiza Cadoret-Manier - 02 Feb 2024 Form 4/A - Amendment Insider Report for IONIS PHARMACEUTICALS INC (IONS)
- Reporting relationship
- EVP,Chf GL Pdt Str & Oper Ofc
- Issuer ticker
- IONS
- Reported as of
- 02 Feb 2024
- Net transaction value
- -$107,240
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 04 Sep 2024, 20:42:24 UTC
- Original report date
- 02 Feb 2024
- Prior SEC filing
- 02 Feb 2024
- Next SEC filing
- 07 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- Patrick R. O'Neil, attorney-in-fact For: Onaiza Cadoret-Manier
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Onaiza Cadoret-Manier filed Form 4/A - Amendment for IONIS PHARMACEUTICALS INC (IONS) on 04 Sep 2024.
Change
- Previous filing in this sequence was filed on 02 Feb 2024.
- Current net transaction value: -$107,240.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IONS
transaction
Common Stock
Sale
- Transaction value
- $107,240
- Shares
- -2,162
- Change %
- -5.7%
- Price
- $49.60
- Shares after
- 35,788
- Date
- 02 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The original Form 4 filed on February 2, 2024 reported 2,125 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Ms. Cadoret-Manier.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.60 to $49.62 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.